2025.07. 14 本文字数：2785，阅读时长大约5分钟 作者 | 第一财经 钱童心 今年上半年，我国批准了45个创新医疗器械产品，此外，国家组织外周血管支架类医用耗材集采中 选结果已在全国多省市落地执行。 第一财经记者从多方了解到，外周小血管覆膜支架自集采落地以来出现供应紧张，但相关的国产器械 正在加速研发，填补巨大的市场空白。 进口产品供应不稳定 根据第五批高值医用耗材集中带量采购中选结果，包括雅培、波士顿科学、百多力等跨国企业，以及 归创通桥、心脉医疗等国内企业在内的18家中选，过去数万元的支架集采的中标价格普遍在三四千 元，最低价格仅2000多元，平均降价幅度超过80%。此前采购需求量最大的戈尔在第五批集采中出 局。 戈尔的自膨式覆膜外周血管支架VIABHAN是此前临床上应用的唯一一款覆膜支架，随着戈尔的出 局，近期有天津、武汉等多地医生反映，这款支架目前供应越来越紧张，临床上还没有太合适的替代 品。 一位三甲医院血管外科医生告诉第一财经记者："覆膜支架是血管外科手术中常用的高值耗材，进口 的戈尔外周小血管覆膜支架确实没有了，大血管的还有。国产的大血管覆膜支架可以从一定程度上替 代，但小血管覆膜 ...

内容概况：根据海关总署数据显示，2025年1-5月，中国血管支架进口数量为91.40万个，同比下降 38.18%；进口金额为11.54亿元，同比下降18.70%，形成量价同降局面。一是国产高端产品加速替代， 如微创医疗Firesorb®生物可吸收支架技术突破，减少对进口依赖；二是集采政策深化，进口支架中标 价大幅压缩，医疗机构采购策略转向性价比更高的国产产品。同期，中国血管支架出口数量为28.89万 个，同比增长30.09%；出口金额为2.43亿元，同比增长24.03%。随着国产支架技术成熟度提升，如乐普 医疗NeoVas®通过欧盟CE认证，有效打开了国际市场。 相关上市企业：心脉医疗（688016）、乐普医疗（300003）、凯利泰（300326）、赛诺医疗 （688108）、蓝帆医疗（002382） 相关企业：洛阳双瑞精铸钛业有限公司、宝鸡钛业股份有限公司、西部超导材料科技股份有限公司、宝 武特种冶金有限公司、浙江华友钴业股份有限公司、南京寒锐钴业股份有限公司、青海金广镍铬材料有 限公司、万华化学集团股份有限公司、山东东岳高分子材料有限公司、中昊晨光化工研究院有限公司、 华东医药股份有限公司、华北制药股份 ...

Core Insights - The reliance on imported high-value medical consumables in China is decreasing as domestic brands emerge in critical areas such as intracranial aneurysm embolization devices, cardiac sutures, heart valves, artificial blood vessels, and ECMO consumables [1][4] - In the first half of this year, China approved 45 innovative medical device products, and the results of centralized procurement for peripheral vascular stents have been implemented in multiple provinces [1][2] Group 1: Market Dynamics - The fifth batch of centralized procurement results shows that 18 companies, including both multinational and domestic firms, have been selected, with prices for stents dropping by over 80% [2][3] - The exit of Gore from the procurement process has led to supply shortages for its self-expanding covered peripheral vascular stent, VIABHAN, which was previously the only option for small vessels [2][3] - The demand for peripheral vascular implants is significant, with 200,000 to 300,000 patients treated annually, yet domestic products currently hold less than 10% of the procurement share [3] Group 2: Challenges in Domestic Production - Domestic manufacturers are developing products to compete with Gore's stent, but face challenges in material quality and production processes [4][5] - The production of small vascular covered stents is particularly challenging due to stringent requirements for flexibility, support, and leakage prevention [3][4] - The heart suture market remains dominated by imports, with no domestic alternatives currently available for critical applications [6][7] Group 3: Clinical Implications - The shortage of small vascular covered stents has forced clinicians to seek temporary procurement solutions, which can take one to two weeks [3] - In pediatric cardiac care, the lack of suitable domestic devices leads to reliance on adult products, creating operational delays [7][8] - The mechanical valve market in China is largely unaddressed by domestic manufacturers, with only a few multinational companies providing these products [7][8] Group 4: Future Outlook - The potential for supply shortages in specific medical device areas exists if domestic solutions are not developed in time [9] - The market for interventional valves is attractive due to shorter development cycles and higher profit margins, which may incentivize domestic companies to invest [8]

Core Viewpoint - The article highlights China's commitment to sharing its healthcare insurance experiences with developing countries, particularly through a recent training program aimed at enhancing medical security capabilities in Africa and Southeast Asia [1][2][12]. Group 1: Training Program Overview - The training program was the first of its kind organized by China for developing countries, marking a significant milestone in international healthcare cooperation [1]. - It involved 50 government representatives and experts from 12 countries, focusing on China's healthcare insurance system and its practical experiences [2][4]. - The program included lectures from officials of the National Healthcare Security Administration, showcasing China's journey from "lack of medical resources" to "universal healthcare" [4][5]. Group 2: Key Insights on China's Healthcare System - The training emphasized the importance of universal coverage as the foundation for public health, with a focus on mutual assistance and basic security [4][5]. - Participants learned about China's centralized procurement mechanisms for medicines and medical supplies, which have made healthcare more accessible and affordable [8][10]. - The program also addressed the challenges faced by developing countries in establishing effective healthcare systems, with China offering its experiences as potential solutions [12][13]. Group 3: Opportunities for Chinese Pharmaceutical Companies - The training provided a platform for Chinese pharmaceutical companies to showcase their products and explore international markets, particularly in Southeast Asia and Africa [8][10]. - Participants expressed interest in the quality and pricing of Chinese medical products, indicating a potential market for these products in their home countries [8][9]. - The program highlighted the support from the Chinese government for domestic companies to expand internationally, enhancing their competitiveness in global markets [9][10].

Core Viewpoint - The training program on medical insurance capacity building for developing countries, hosted by China, marks a significant milestone in international cooperation in healthcare, focusing on sharing experiences and enhancing collaboration with African and Southeast Asian nations [1][10]. Group 1: Training Program Overview - The training program involved 50 government representatives and experts from 12 countries, emphasizing China's commitment to sharing its medical insurance experiences [1]. - The program served as a platform for discussing key issues in global healthcare, including the construction of medical insurance systems and the reduction of drug prices [3][10]. - Participants engaged in practical sessions, including site visits to Chinese medical institutions and discussions on China's centralized procurement mechanisms [1][8]. Group 2: Insights on China's Medical Insurance System - China's medical insurance system, which covers over 1.3 billion people, is viewed as a model for developing countries seeking to establish sustainable healthcare systems [5]. - The program highlighted the importance of universal coverage as a fundamental guarantee for public health, with insights shared on China's policies and mechanisms for achieving this goal [3][10]. - The training addressed various aspects of medical assistance, including the identification of beneficiaries and the role of different departments in providing support [4][10]. Group 3: Opportunities for Chinese Pharmaceutical Companies - The training facilitated connections between Chinese pharmaceutical companies and representatives from developing countries, showcasing the potential for collaboration in healthcare [6][11]. - Participants expressed interest in the quality and affordability of Chinese medical products, with discussions on the challenges and opportunities for Chinese companies to enter international markets [6][9]. - The program emphasized the strategic importance of centralized procurement in enhancing the competitiveness of Chinese medical products abroad [9][10]. Group 4: Future Collaboration and Impact - The training is seen as a bridge connecting China's medical insurance solutions with the healthcare needs of African and Southeast Asian countries, fostering long-term partnerships [11]. - Representatives from various countries expressed optimism about applying the knowledge gained to improve their own healthcare systems and enhance cooperation with China [10][11]. - The initiative is expected to contribute to addressing the challenges of "difficult and expensive medical care" in developing countries [10].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月19日，思宇MedTech和Medtec China联合主办的 2025医疗器械研发论坛 上， 北京阿迈特医疗器械有限公司高级研发工程师、北京市高级工程师杨鹏 先生 ，分享了题为 《3D打印全降解血管支架的技术突破与临床应用》 的精彩内容。 思宇MedTech提炼要点回顾如下，希望对医疗器械行业读者有所启发。 一、3D打印全降解血管支架的发展背景 心血管疾病是全球范围内导致死亡的主要疾病之一，冠心病、脑卒中及外周动脉疾病影响着数千万患者。 二、全球可降解支架的技术挑战 雅培公司开发第一个用于人体的可降解血管支架，并在2011年获得CE认证，2016年获得FDA批准。然而，由于血栓发生率高、降解周期过长、长期靶病变失败 风险增加等问题，2017年雅培全球召回该产品。 目前，市场上仍未有一款成熟的可降解支架产品能够完全解决上述问题，这使得新一代技术路线的探索成为关键。 传统可降解支架多采用激光切割技术，从管材加工而成，该工艺存在工艺复杂、成品率 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月19日， 2025医疗器械研发创新论坛 在北京量子银座成功举办。 本次论坛以 "智能化时代下的植介入器械" 为主题，由 Informa Markets旗下Medtec China团队 和 思宇MedTech医疗科技新媒体矩阵 共同主办，并由北京集智未 来人工智能产业创新基地有限公司、启迪之星联合承办。 论坛吸引了120余位行业专家、企业代表和投资机构人士参会，共同探讨智能化技术如何推动植入介入医 疗器械的创新发展。 # 行业专家齐聚，共话技术创新 论坛伊始， Medtec医疗器械设计与制造技术展项目总监蔡锋 在致辞中表示，Medtec一直致力于推动医疗器械创新， Medtec展览会不仅是一个展示产品和技术的平 台，更是一个连接上下游企业的桥梁。去年 展会的展览面积达45,000平方米，观众数量超过85,000人次，展商数量超过1,000家，同时举办120多场演讲活动 ，内容 丰富多样，覆盖医疗器械供应链从生产到上市的全流程。 2025年国际 ...

随着智能化技术的飞速发展，植入和介入医疗器械的研发迎来了前所未有的机遇和挑战。智能化、精准 化、个性化治疗已成为行业发展趋势， 智能化设备、精确成像技术、可吸收材料等新兴技术的应用，不仅 推动了医疗器械技术的创新，也在重塑整个行业的格局。 如何利用新兴技术提升植介入设备的研发效率、优化临床效果，以及推进高性能材料的应用？ 思宇MedTech联合Informa Market旗下Medtec China团队，策划 2025医疗器械研发创新论坛 ， 面向 研发负责 人、技术决策者，还是产品经理、希望转化成果的医生等 专家，探讨如何通过智能化技术驱动植介入医疗 器械研发创新，探寻未来医疗器械的变革之路。 思宇MedTech医疗科技新媒体矩阵 会议承办单位： 北京集智未来人工智能产业创新基地有限公司 （以下为更新后的完整议程~） 2025医疗器械研发创新论坛 2025 Medical Device R&D Innovation Forum ——智能化时代下的植介入研发 R&D in Implant and Interventional Devices in the Era of Smart Technologies 会 ...

随着智能化技术的飞速发展，植入和介入医疗器械的研发迎来了前所未有的机遇和挑战。智能化、精准 化、个性化治疗已成为行业发展趋势， 智能化设备、精确成像技术、可吸收材料等新兴技术的应用，不仅 推动了医疗器械技术的创新，也在重塑整个行业的格局。 如何利用新兴技术提升植介入设备的研发效率、优化临床效果，以及推进高性能材料的应用？ 思宇MedTech联合Informa Market旗下Medtec China团队，策划 2025医疗器械研发创新论坛 ， 面向 研发负责 人、技术决策者，还是产品经理、希望转化成果的医生等 专家，探讨如何通过智能化技术驱动植介入医疗 器械研发创新，探寻未来医疗器械的变革之路。 论坛将围绕以下主题展开深入讨论： 欢迎希望分享和交流的人士报名~ 2025医疗器械研发创新论坛 2025 Medical Device R&D Innovation Forum ——智能化时代的植介入研发 14:00-14:10 开幕致辞 14:10-14:40 主题演讲：智能化时代的植入介入医疗器械 分享嘉宾： 赵清，思宇 MedTech，主编 R&D in Implant and Interventional D ...

随着智能化技术的飞速发展，植入和介入医疗器械的研发迎来了前所未有的机遇和挑战。智能化、精准 化、个性化治疗已成为行业发展趋势， 智能化设备、精确成像技术、可吸收材料等新兴技术的应用，不仅 推动了医疗器械技术的创新，也在重塑整个行业的格局。 如何利用新兴技术提升植介入设备的研发效率、优化临床效果，以及推进高性能材料的应用？ 思宇MedTech联合Informa Market旗下Medtec China团队，策划 2025医疗器械研发创新论坛 ， 面向 研发负责 人、技术决策者，还是产品经理、希望转化成果的医生等 专家，探讨如何通过智能化技术驱动植介入医疗 器械研发创新，探寻未来医疗器械的变革之路。 论坛将围绕以下主题展开深入讨论： 会议地点： 北京市知春路量子银座（向报名审核通过的朋友通知具体会议室） 智能化设备驱动的植介入研发创新 ： 如何通过机器人、导航技术、智能传感器等智能化手段，先进的 软件技术，提升植介入器械的精准性与微创性。 植介入医疗器械的技术趋势与实际应用 ： 从AI辅助规划到术后远程监控，如何将前沿技术转化为临床 应用，提升医疗效果与患者体验。 高性能材料与可吸收材料的创新 ： 聚焦生物兼容性 ...